Texas Retina Associates’ Post

Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections "This case series describes five cats with cutaneous adverse events after subcutaneous administration of frunevetmab, a felinised anti-nerve growth factor monoclonal antibody, including histopathological findings in one case." https://lnkd.in/gr-NuuRG

Could anti-CD19 CAR T cells also help with rheumatoid arthritis? Our recent case, now published, reports complete clinical remission of both rheumatoid arthritis and myasthenia gravis, along with seroconversion of anti-citrullinated protein antibodies (ACPA). Clinical trials are essential to explore this possibility. Collaboration is crucial for further advancements (Aiden Haghikia Georg Schett Peter Maag). #TeamMagdeburg #UMMD #CARTcells #Autoimmunity #RheumatoidArthritis #Myasthenia #Innovation Read more about our findings [here](https://lnkd.in/ehn5UjQT).

✨ Published in #Cell Reports: The article finds that #PD-L1, produced by #HSCs, is required for HSC activation by stabilizing #TGF-β receptors I (TβRI) and II (TβRII). While the extracellular domain of PD-L1 (amino acids 19–238) targets TβRII protein to the plasma membrane and protects it from lysosomal degradation, a C-terminal 260-RLRKGR-265 motif on PD-L1 protects TβRI #mRNA from degradation by the #RNA #exosome complex. Myofibroblast PD-L1 can modulate the tumor microenvironment and tumor growth by a mechanism independent of immune suppression. 🎈 Related Product Recommendation: #Durvalumab Durvalumab (#MEDI 4736) is an human anti-PD-L1 monoclonal #antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with #IC50s of 0.1 and 0.04 nM, respectively. 👉 https://lnkd.in/gswzaCZh For more detailed information: https://lnkd.in/gRuQ-V8p

At #ESMO24, late-breaking primary results from the DESTINYBreast-12 trial revealed substantial and durable efficacy with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in patients with HER2+ metastatic #BreastCancer, including those with brain metastases. Encouraging data were also presented from the smaller ICARUS-BREAST01 study with the novel anti-HER3 ADC patritumab deruxtecan in patients with HR+/HER2- #AdvancedBreastCancer after failure of CDK-4/6 inhibitor therapy. 👉Read the full-data commentary by Philippe Aftimos MD on the #ESMODailyReporter https://ow.ly/gRCQ50TmTCX

JUST OUT, FDA approved osimertinib for adult patients with stage III non-small cell #LungCancer #NSCLC that is locally advanced and unresectable, specifically for those whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations This approval applies to patients whose disease has not progressed following platinum-based chemoradiation therapy. The approval was based on the LAURA trial, which showed osimertinib significantly improved progression-free survival (PFS) compared to placebo, with a median PFS of 39.1 months versus 5.6 months. https://lnkd.in/drQQ4Y83

Late-Breaking primary results from the phase IIIb/IV, open-label DESTINYBreast-12 trial revealed substantial and durable efficacy in 504 patients with HER2-positive metastatic breast cancer, including those with brain metastases (LBA18). In the cohort with brain metastases (n=263), the 12-month progression-free survival (PFS) rate was 61.6%, while the 12-month central nervous system (CNS) PFS was 58.9%, with similar results in those with stable (PFS, 57.8%) and active (PFS, 60.1%) brain metastases. The 504 patients enrolled in the open-label trial had experienced disease progression on ≤2 prior lines of therapy

REGENXBIO Inc. provided a clinical and regulatory update on their Duchenne muscular dystrophy program highlighting progress in dose selection for their upcoming pivotal study which is expected to begin dosing patients in late Q3 2024 to early Q4 2024. In new data announced today from the second patient (aged 8.1 years) at dose level 2 from the Phase I/2 AFFINITY DUCHENNE trial, RGX-202 microdystrophin expression was measured to be 20.9% compared to control at three months and this was this accompanied with a reduction in serum creatinine kinase levels of 90% at 10 weeks. RGX-202 continues to be well tolerated in all patients with no serious adverse events, and they expect to enroll up to a total of seven patients at the pivotal dose through early Q3 2024. Further details on the corporate update can be found in the link below. https://lnkd.in/gnyQBfA2 #DMD #duchenne #clinicaltrials #CureDuchenne

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Ivonescimab, a revolutionary bispecific antibody developed by Akeso Biopharma, merges PD-1 immunotherapy blockade with anti-VEGF angiogenesis inhibition in one innovative formulation. A pivotal Phase III (HARMONi-A trial) is currently underway, assessing ivonescimab combined with chemotherapy in EGFR-mutated, locally advanced, or metastatic non-squamous NSCLC patients who have progressed after third-generation EGFR TKI treatment. Enrollment is expected to conclude in the latter half of 2024. Tap into Expert Insights and Detailed Analysis with DelveInsight Business Research LLP's Exclusive Coverage of American Society of Clinical Oncology (ASCO) 2024! https://lnkd.in/gR77RGnt #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Want to know more about the benefits of integrating quantitative MRI with traditional biomarkers in GLP-1 clinical trials? Our team will be presenting tomorrow at the GLP-1-Based Therapeutics Summit. Don't miss Dr. Tom Waddell's 2:00 pm EST talk on, "Uncovering the Hidden Benefits of GLP-1s Using Quantitative MRI: From Obesity to Obstructive Sleep Apnea & Everything In Between."